Abstract 571P
Background
Brain metastases (BM) are common among EGFRm NSCLC patients. And it has been associated with treatment failure and limited survival especially patients with multiple BMs. Dacomitinib is a selective, irreversible, Pan-HER TKI. It brought significant PFS and OS improvement compared with Gefitinib in phase 3 randomize study ARCHER 1050. However, patients with BM or leptomeningeal metastases were excluded in this study. We hereby conducted this phase II study (NCT02047747) to prospectively evaluate the efficacy and safety of Dacomitinib in NSCLC patients with multiple BMs and here are initial results of this study.
Methods
Treatment-naive stage IIIB/IV EGFR-mutant NSCLC patients with multiple and measurable BMs(≥ 3 metastatic lesions in the brain and at least 1 target lesion’s diameter among these lesions should be ≥1 cm) received Dacomitinib45mg orally once daily. Assessments were performed every8 weeks until disease progression (PD) as per RECIST v1.1. End points included PFS, intracranial ORR (iORR), ORR, and safety.
Results
At data cut-off (Jul 1, 2023), a total of 14 patients were enrolled and the median follow-up time was 24 months (range, 4-28m), of which 10 patients had measurable CNS response. For all patients, the mPFS was 15.3m(8/14),ORR was 78.6% while DCR was 100%.The iORR was 80% and iDCR was 100%. The mPFS in patients with 19Del (8/14,57.1%) and21L858R (6/14,42.9%) are 15.3 and 15.2m, ORR are 87.5% and 66.7%, respectively. There are no new adverse events (AEs) compared to ARCHER1050.The most common AEs were rash (10/14; 71.4%), diarrhea (8/14; 57.1%), paronychia (3/14; 21.4%). Temporary discontinuations and dose modification occurred in 2 (14.3%) and 1 (7.1%) patient, respectively.
Conclusions
Dacomitinib showed promising intracranial antitumor activity with a manageable safety profile as first-line therapy in EGFR-mutant NSCLC patients with multiple brain metastases.
Clinical trial identification
NCT02047747.
Editorial acknowledgement
Legal entity responsible for the study
Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Funding
Pfizer.
Disclosure
Y. Yu: Financial Interests, Personal, Invited Speaker: Pfizer, AstraZeneca, Rohce, MSD. Y. Pan: Financial Interests, Personal, Advisory Board: Pfizer, AstraZeneca, Roche, MSD; Financial Interests, Personal, Invited Speaker: Pfizer. J. Zhou: Financial Interests, Personal, Invited Speaker: Pfizer, AstraZeneca, Roche, MSD. S. Lu: Financial Interests, Institutional, Invited Speaker: Hansoh, AstraZeneca, Roche, Hengrui; Financial Interests, Institutional, Advisory Board: AstraZeneca, Prizer, Boehringer Ingelheim, Hutchison MediPharma, ZaiLab, GenomiCare, Yuhan Corporation, Menarini, InventisBio Co.Ltd, Roche, Simcere Zaiming Pharmaceutical Co., Ltd.; Financial Interests, Personal, Research Grant: AstraZeneca, Hutchison, BMS, Heng Rui, Roche, Hansoh, BeiGene, Lilly Suzhou Pharmaceutical Co.Ltd; Financial Interests, Personal, Coordinating PI: FibroGen.
Resources from the same session
549P - Drug-induced interstitial lung disease in patients with non-small cell lung cancer treated with immunotherapy for postoperative recurrence: Evaluation of CT findings and histopathological findings of the background lung
Presenter: shodai fujimoto
Session: Poster Display
Resources:
Abstract
551P - Real-world incidence and outcomes of immune-related adverse events in NSCLC patients
Presenter: Andrea Knox
Session: Poster Display
Resources:
Abstract
552P - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
Presenter: Yasushi Goto
Session: Poster Display
Resources:
Abstract
553P - Preceding plasma EGFR vs upfront tissue NGS for advanced NSCLC in the Chinese population: A single centre experience in Hong Kong
Presenter: Janet Du
Session: Poster Display
Resources:
Abstract
554P - Comparison of the analytical performance of endobronchial ultrasound-guided transbronchial needle aspiration and other sampling methods for the Oncomine Dx target test: An observational study
Presenter: Kazuhito Miyazaki
Session: Poster Display
Resources:
Abstract
555P - Quality of life in patients with stage IV non-small cell lung cancer and the influence of druggable mutations over time: A prospective, territory-wide study in Hong Kong
Presenter: Jason C S Ho
Session: Poster Display
Resources:
Abstract
556P - Results from the phase I study on efficacy and safety of iruplinalkib (WX-0593) for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who received prior second-generation ALK tyrosine kinase inhibitors (TKIs)
Presenter: xuezhi Hao
Session: Poster Display
Resources:
Abstract
557P - Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy
Presenter: Shasha Wang
Session: Poster Display
Resources:
Abstract
558P - Treatment duration and adherence of brigatinib as second-line treatment after crizotinib for ALK+ NSCLC in South Korea
Presenter: Jeong Eun Lee
Session: Poster Display
Resources:
Abstract
559P - Comprehensive survey of AACR GENIE database revealed a wide range of TMB distribution among all three classes (I, II, III) of BRAF mutated NSCLC
Presenter: Zhaohui Arter
Session: Poster Display
Resources:
Abstract